Antiplatelet agents for chronic kidney disease
is a topic covered in the Evidence-Based Medicine Guidelines
To view the entire topic, please sign in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
"Antiplatelet Agents for Chronic Kidney Disease." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/458127/all/Antiplatelet_agents_for_chronic_kidney_disease.
Antiplatelet agents for chronic kidney disease. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/458127/all/Antiplatelet_agents_for_chronic_kidney_disease. Accessed March 23, 2019.
Antiplatelet agents for chronic kidney disease. (2019). In Evidence-Based Medicine Guidelines. Available from https://evidence.unboundmedicine.com/evidence/view/EBMG/458127/all/Antiplatelet_agents_for_chronic_kidney_disease
Antiplatelet Agents for Chronic Kidney Disease [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2019 March 23]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/458127/all/Antiplatelet_agents_for_chronic_kidney_disease.
TY - ELEC
T1 - Antiplatelet agents for chronic kidney disease
ID - 458127
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/458127/all/Antiplatelet_agents_for_chronic_kidney_disease
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine